ANI Pharmaceuticals(US:ANIP) ZACKS·2025-10-15 17:11Core Viewpoint - ANI Pharmaceuticals is positioned well to potentially beat earnings estimates in its upcoming quarterly report, supported by a strong history of exceeding expectations [1]. Earnings Performance - ANI Pharmaceuticals has a solid track record of surpassing earnings estimates, with an average surprise of 27.26% over the last two quarters [2]. - In the last reported quarter, ANI achieved earnings of $1.8 per share, exceeding the Zacks Consensus Estimate of $1.38 per share by 30.43%. In the previous quarter, the company reported earnings of $1.7 per share against an expectation of $1.37 per share, resulting in a surprise of 24.09% [3]. Earnings Estimates and Predictions - Recent estimates for ANI have been trending upward, with a positive Earnings ESP (Expected Surprise Prediction) indicating a strong likelihood of an earnings beat [6]. - The Zacks Earnings ESP for ANI is currently +1.15%, suggesting that analysts have recently become more optimistic about the company's earnings prospects. This positive Earnings ESP, combined with a Zacks Rank of 2 (Buy), indicates a potential for another earnings beat [9]. Statistical Insights - Research indicates that stocks with a positive Earnings ESP and a Zacks Rank of 3 (Hold) or better have a nearly 70% chance of producing a positive surprise [7]. - The Earnings ESP metric compares the Most Accurate Estimate to the Zacks Consensus Estimate, with the Most Accurate Estimate reflecting the latest analyst revisions, which may be more accurate than earlier predictions [8].